Sensus Healthcare (NSDQ:SRTSU) said today it closed its initial public offering, raising $11 million through the sale of 2.3 million units at $5.50 each.
The offering included a fully-exercised underwriters option of an additional 300,000 units at the IPO price, Sensus said. Each share consists of a unit of stock and a 3-year warrant with an exercise price of $6.75. The offering units are slated to split by July 25, with the stock shares trading on the NASDAQ exchange under the “SRTS” symbol and the warrants under the “SRTSW” symbol.
Sensus makes low-energy photon X-ray systems for treating non-melanoma skin cancers, including basal cell and squamous cell carcinomas, and keloids. The company said March 9 that it planned to float more than 1.8 million shares at $10 to $12 apiece, working out to a low-end raise of $18.2 million and a high end of $21.8 million. Later that month, Sensus postponed the IPO. Last month, Sensus scaled back, saying it planned to offer 1.75 million shares at $6.25 apiece, for gross proceeds of $10.9 million.
The SRT-100 system has U.S. 510(k) clearance, CE Mark approval in the European Union and approvals from the China Food & Drug Administration and Health Canada; Sensus claims more than 200 installed devices in 11 countries.
The company had planned to put $3 million of the IPO proceeds toward hiring new sales reps and a director of marketing, and another $3 million into R&D for new products and the further development of existing products. Some $2.7 million was to have gone toward paying a dividend to a former shareholders who elect not to convert their dividends into shares after the IPO, Sensus has said.
Northland Securities, Inc., and Neidiger, Tucker, Bruner, Inc. acted as joint book-running managers for the offering, to a press release.